| AE | adverse event |
| CRO | contract research organization |
| DNA | deoxyribonucleic acid |
| ECM | extracellular matrix |
| EMA | European Medicines Agency |
| FDA | Food and Drug Administration |
| G′ | storage modulus |
| G″ | loss modulus |
| GAIS | Global Aesthetic Improvement Scale |
| GCP | good clinical practices |
| HA | hyaluronic acid |
| IGAIS | Investigator Global Aesthetic Improvement Scale |
| ISR | injection site reactions |
| ITA | individual typological angle |
| LED | light-emitting diode |
| mRNA | messenger ribonucleic acid |
| NA | non-applicable |
| ns | non-significant |
| Pa | Pascals |
| Pa·s | Pascal seconds |
| PGE2 | prostaglandin E2 |
| ROS | reactive oxygen species |
| s | second |
| SAE | serious adverse event |
| SGAIS | Subject Global Aesthetic Improvement Scale |
| TGF | transforming growth factor |
| TXA | tranexamic acid |
| USA | United States of America |
| UV | ultraviolet |
| UVA | ultraviolet A |
| UVB | ultraviolet B |